Cytosorbents Corp cotiza a 3.59 USD y tiene una capitalización bursátil de $11M. En los últimos 12 meses ha facturado $37M con un margen de flujo de caja libre del -33.8%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in commo…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-1.40 | $-1.60 | $-1.80 |
| Estimado | $-0.90 | $-0.90 | $-1.10 | $-1.00 |
| Sorpresa | — | -55.6% | -45.5% | -80.0% |
| Métrica | CTSO | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 71.5% | 57.0% | +14.4% |
| Operating Margin | -39.8% | -38.6% | -1.2% |
| Net Margin | -22.1% | -33.6% | +11.4% |
| FCF Margin | -33.8% | -13.9% | -20.0% |
| ROE | -138.9% | -40.4% | -98.5% |
| ROA | -18.6% | -32.0% | +13.4% |
| Current Ratio | 2.13 | 2.84 | -0.71 |
| Debt / Equity | 2.82 | 0.28 | +2.54 |